SELL TO SCIENTISTS.

Fields

Translational Medicine

Translational medicine accelerates the bidirectional flow of knowledge between basic biomedical research and clinical practice. Adaptive clinical trial designs respond to accumulating data by modifying randomization ratios, doses, or endpoints in real time, increasing efficiency and reducing patient exposure to inferior treatments. Patient-derived organoids replicate tumor drug sensitivity ex vivo to predict clinical response, informing personalized oncology decisions. Multi-omics biomarker panels stratify patient populations by molecular subtype, enabling responder-enriched trials that detect efficacy signals obscured in unselected populations. The COVID-19 pandemic demonstrated the potential for platform trial infrastructure to evaluate multiple therapies simultaneously, shortening development timelines from years to months when urgency demands it.

Details

Avg Funding
$680K
Key Technologies
Patient-Derived OrganoidsAdaptive Clinical TrialsMulti-Omics StratificationDigital BiomarkersAI Patient Stratification
Subfields
Biomarker DevelopmentClinical Trial DesignDrug RepurposingPrecision MedicinePatient-Derived Models
Top Institutions
NIH Clinical CenterAcademic Medical Center AmsterdamKing College LondonUniversity of TorontoSingapore General Hospital
Get Started